NCT02210559 - A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 15, 2021

Study Completion Date

December 15, 2021

Conditions

Pancreatic Cancer (Unresectable)

Interventions

DRUG

FG-3019

FG-3019 will be administered per dose and schedule specified in the arm group description.

DRUG

Gemcitabine

Gemcitabine will be administered per dose and schedule specified in the arm group description.

DRUG

Nab-paclitaxel

Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.

Trial Locations (8)

Thomas Jefferson University, Philadelphia

Georgetown University - Medstar Health Research Institute, Washington D.C.

Mayo Clinic Florida, Jacksonville

Virginia Piper Cancer Institute, Minneapolis

Ochsner Clinic Foundation, New Orleans

HonorHealth Research Institute, Scottsdale

University of California, Los Angeles, Los Angeles

Virginia Mason Medical Center - Benaroya Research Institute, Seattle